Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.
Piccaluga
Pier Paolo
PP
Malagola
Michele
M
Rondoni
Michela
M
Amabile
Marilina
M
Paolini
Stefania
S
Soverini
Simona
S
Gaitani
Stavroula
S
Visani
Giuseppe
G
Baccarani
Michele
M
Martinelli
Giovanni
G
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage; D001549:Benzamides; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009364:Neoplasm Recurrence, Local; D010879:Piperazines / Q000008:administration & dosage* / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000628:therapy; D011241:Prednisone / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage* / Q000627:therapeutic use; D012074:Remission Induction; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous; D014750:Vincristine / Q000008:administration & dosage
D001549:Benzamides; D009363:Neoplasm Proteins; D010879:Piperazines; D011743:Pyrimidines; D014750:Vincristine; D004317:Doxorubicin; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D001215:Asparaginase; D011241:Prednisone